Statins and the risk of colorectal cancer: A meta-analysis of 18 studies involving more than 1.5 million patients

Journal of Clinical Oncology

Volumn 25, Issue 23, 2007, Pages 3462-3468

  Bonovas, Stefanos ^a   Filioussi, Kalitsa ^a   Flordellis, Christodoulos S ^a   Sitaras, Nikolaos M ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG USE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMATIC REVIEW;

ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; RISK; TREATMENT OUTCOME;

EID: 34548019063     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.8936     Document Type: Article

References (56)

1. Walley T, Folino-Gallo P, Schwabe U, et al: Variations and increase in use of statins across Europe: Data from administrative databases. BMJ 328:385-386, 2004
2. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990
3. Kim KP, Whitehead C, Piazza G, et al: Combinatorial chemoprevention: Efficacy of lovastatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 24:1805-1811, 2004
4. Agarwal B, Rao CV, Bhendwal S, et al: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117:838-847, 1999
5. Narisawa T, Morotomi M, Fukaura Y, et al: Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87:798-804, 1996
6. Narisawa T, Fukaura Y, Tanida N, et al: Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine- induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 180:131-138, 1996
7. Narisawa T, Fukaura Y, Terada K, et al: Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 15:2045-2048, 1994
8. Poynter JN, Gruber SB, Higgins PD, et al: Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192, 2005
9. Hawk E, Viner JL: Statins and cancer: Beyond the "one drug, one disease" model. N Engl J Med 352:2238-2239, 2005
10. Graaf MR, Beiderbeck AB, Egberts AC, et al: The risk of cancer in users of statins. J Clin Oncol 22:2388-2394, 2004
11. Kaye JA, Jick H: Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90:635-637, 2004
12. Friis S, Poulsen AH, Johnsen SP, et al: Cancer risk among statin users: A population-based cohort study. Int J Cancer 114:643-647, 2005
13. Blais L, Desgagne A, LeLorier J: 3-Hydroxy-3methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 160:2363-2368, 2000
14. Bjerre LM, LeLorier J: Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110:716-723, 2001
15. Dale KM, Coleman CI, Henyan NN, et al: Statins and cancer risk: A meta-analysis. JAMA 295:74-80, 2006
16. Bonovas S, Filioussi K, Tsavaris N, et al: Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24:4808-4817, 2006
17. Bonovas S, Filioussi K, Tsavaris N, et al: Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606-8612, 2005
18. Greenland S: A critical look at some popular meta-analytic methods. Am J Epidemiol 140:290-296, 1994
19. Emerson JD, Burdick E, Hoaglin DC: An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. Control Clin Trials 11:339-352, 1990
20. Jüni P, Witschi A, Bloch R, et al: The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282:1054-1060, 1999
21. Greenland S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1-30, 1987
22. Altman DG, Bland JM: Interaction revisited: The difference between two estimates. BMJ 326:219, 2003
23. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
24. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
25. Petitti DB: Meta-analysis, decision analysis and cost-effectiveness analysis. New York, NY, Oxford University Press, 1994, pp 90-114
26. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
27. Egger M, Smith GD, Schneider M, et al: Bias in meta-analysis detected by a simple graphical test. BMJ 315:629-634, 1997
28. Cochran WG: The combination of estimates from different experiments. Biometrics 10:101-129, 1954
29. Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558, 2002
30. Higgins JPT, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003
31. Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: A proposal for reporting - Meta-analysis of Observational studies in Epidemiology (MOOSE) Group. JAMA 283:2008-2012, 2000
32. Moher D, Cook DJ, Eastwood S, et al: Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement - Quality of Reporting of Meta-analyses. Lancet 354:1896-1900, 1999
33. Strandberg TE, Pyorala K, Cook TJ, et al: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771-777, 2004
34. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial - Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007, 2002
35. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22, 2002
36. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease): Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 359:1379-1387, 2002
37. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS - Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622, 1998
38. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009, 1996
39. Setoguchi S, Glynn RJ, Avorn J, et al: Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27-33, 2007
40. Coogan PF, Smith J, Rosenberg L: Statin use and the risk of colorectal cancer. J Natl Cancer Inst 99:32-40, 2007
41. Vinogradova Y, Hippisley-Cox J, Coupland C, et al: Risk of colorectal cancer in patients taking statins and non-steroidal anti-inflammatory medication: Nested case control study. Presented at 34th Annual Meeting of the North American Primary Care Research Group (NAPCRG), October 15-18, 2006, Tucson, AZ (abstr W1)
42. Li L, Thompson C, Tucker T: No association between lipid-lowering statin use and risk of colon cancer. Presented at 34th Annual Meeting of the North American Primary Care Research Group (NAPCRG), October 15-18, 2006, Tucson, AZ (abstr CC7)
43. Jacobs EJ, Rodriguez C, Brady KA, et al: Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 98:69-72, 2006
44. Rubin DT, Blumentals WA, Sheer RL, et al: Statins and risk of colorectal cancer: Results from a large case-control study. Am J Gastroenterol 100:394s, 2005 (suppl; abstr 1086)
45. Khurana V, Jaganmohan S, Chalasani R, et al: Statins do not reduce colon cancer risk in humans: A case-control study in half million veterans. Am J Gastroenterol 99:242s, 2004 (suppl; abstr 746).
46. Easterbrook PJ, Berlin JA, Gopalan R, et al: Publication bias in research. Lancet 337:867-872, 1991
47. Simes JR: Publication bias: The case for an international registry of trials. J Clin Oncol 4:1529-1541, 1986
48. Sterling TD, Rosenbaum WL, Weinkam JJ: Publication decisions revisited: The effect of the outcome of statistical tests on the decision to publish and vice versa. Am Statist 49:108-112, 1995
49. Thomsen RW, Johnsen SP, Olesen AV, et al: Socioeconomic gradient in use of statins among Danish patients: Population-based cross-sectional study. Br J Clin Pharmacol 60:534-542, 2005
50. Avorn J, Monette J, Lacour A, et al: Persistence of use of lipid-lowering medications: A cross-national study. JAMA 279:1458-1462, 1998
51. Mamdani MM, Tu K, Austin PC, et al: Influence of socioeconomic status on drug selection for the elderly in Canada. Ann Pharmacother 36:804-808, 2002
52. Ward PR, Noyce PR, St Leger AS: Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross-sectional analysis in four primary care trusts in England. J Epidemiol Community Health 58:89-96, 2004
53. Reid FD, Cook DG, Whincup PH: Use of statins in the secondary prevention of coronary heart disease: Is treatment equitable? Heart 88:15-19, 2002
54. Brown AF, Gross AG, Gutierrez PR, et al: Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care. J Am Geriatr Soc 51:665-670, 2003
55. Ward E, Jemal A, Cokkinides V, et al: Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54:78-93, 2004
56. Freeman HP: Cancer in the socioeconomically disadvantaged. CA Cancer J Clin 39:266-288, 1989